Phase I Trial of CD19-Targeted CAR-Modified T Cells as Consolidation for Previously Untreated CLL
Park JH et al. Phase I trial of autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL. Proc ASH 2013; Abstract 874.
Dr Porter is Jodi Fisher Horowitz Professor of Leukemia Care Excellence and Director of Blood and Marrow Transplantation at the University of Pennsylvania Health System's Abramson Cancer Center in Philadelphia, Pennsylvania.
|